Capricor reviews operations after FDA rejects cell therapy Deramiocel
FROM THE WIRE · SEEKINGALPHA.COM
[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images Capricor Therapeutics (CAPR [https://seekingalpha.com/symbol/CAPR]) announced that its operating expenses are under review after the U.S. Food and Drug Administration on Friday declined to approve…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA second FDA rejection of its key candidate weighs on the company's outlook and costs.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA issued a Complete Response Letter on the resubmitted BLA for Deramiocel.
- 02The one-time therapy targets Duchenne muscular dystrophy, a rare neuromuscular disorder.
- 03The FDA attributed the decision to concerns over the drug's effectiveness, among other issues.
- 04Capricor is reviewing its operating expenses.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets